PB 120 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 11)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated    29 November 2021

NIKOLAI TSYGANOV

Contents

1 Name…………………………………………………………………………….………………1

2 Commencement

3 Authority

4  Schedule

Schedule 1—Amendments 2

National Health (Continued Dispensing - Emergency Measures) Determination 2020 2

1 Name

(1)           This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 11).

(2)           This instrument may also be cited as PB 120 of 2021.

2 Commencement

(1)           Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)           Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1]           Schedule 1, entry for Desmopressin

omit:

[2]           Schedule 1, after entry for High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate in the form Oral liquid 250 mL, 30 (KetoVie 4:1)

insert:

[3]           Schedule 1, entry for Imipramine

omit:

[4]           Schedule 1, after entry for Lamotrigine in the form Tablet 50 mg

insert:

[5]           Schedule 1, entry for Ribavirin

insert as first entry:

[6]           Schedule 1, after entry for Riluzole in the form Tablet 50 mg

insert:

[7]           Schedule 1, entry for Testosterone

omit: